Tests baxdrostat with dapagliflozin to prevent heart failure in people with diabetes
Tests baxdrostat added to dapagliflozin in adults with type 2 diabetes and heart disease.
Plain-language title generated from the registry record
Registry title: Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Key facts
- Where
- Angeles City, Cebu, Davao City, Fuente Osmena Cebu City, Iloilo City, Las Piñas, Lipa City, Manadaluyong City, Puerto Princesa City, Quezon City, and Roxas City, PhilippinesSee the 11 sites
- Phase
- Phase 3
Where in Philippines
- Angeles CityAngeles City, PhilippinesTaking people
- CebuCebu, PhilippinesTaking people
- Davao CityDavao City, PhilippinesTaking people
- Fuente Osmena Cebu CityFuente Osmena Cebu City, PhilippinesTaking people
- Iloilo CityIloilo City, PhilippinesTaking people
- Las PiñasLas Piñas, PhilippinesTaking people
- Lipa CityLipa City, PhilippinesTaking people
- Manadaluyong CityManadaluyong City, PhilippinesNo longer taking part
- Puerto Princesa CityPuerto Princesa City, PhilippinesTaking people
- Quezon CityQuezon City, PhilippinesTaking people
- Roxas CityRoxas City, PhilippinesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06677060EU 2024-514506-32-00
- Record updated
- 21 October 2026
- Original description
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF.Read full original descriptionShow less
A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF.
The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1.
Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation.
Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months.
The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD.
In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.
Inclusion: Participants of any sex and gender must be ≥ 40 years old at the time of signing the informed consent; Diagnosed with T2DM and requiring treatment; Established CV disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease); History of HTN and an SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the Randomisation Visit; At least one additional risk factor for HF:; Age ≥ 70 years; UACR > 20 mg/g; eGFR < 60 mL/min/1.73 m2; History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease); History of atrial fibrillation or atrial flutter; NT-proBNP > 125 ng/L.
Exclusion: Previously confirmed diagnosis and treatment of heart failure; Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, carotid angioplasty, or cardiac surgery, within 3 months prior to randomisation; Myocardial infarction within 3 months prior to randomisation, or within 1 month prior to randomisation when there is no further planned revascularisation; Percutaneous coronary intervention within 1 month prior to randomisation; Any dialysis (including for acute kidney injury) within 3 months prior to screening; Any acute kidney injury within 3 months prior to screening; Prohibited concomitant medications; Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history; Documented history of adrenal insufficiency; An eGFR < 30 mL/min/1.73 m2 at screening; Known hyperkalaemia, defined as potassium ≥ 5.5 mmol/L within 3 months prior to screening; Type 1 diabetes mellitus or uncontrolled T2DM with HbA1c > 10.5% (> 91 mmol/mol) at screening; Serum sodium < 135 mmol/L at screening, determined as per central laboratory assessment.